Open company graph database — free web & API
Login

PCI Pharma Services

Ticker
—
Listed market
—
Country
—
Employees (non-consolidated)
—
Related companies
0
§01

Basic information

BASIC
Head office
Sources
Chief executive
Michelle LoganSources
Employees (non-consolidated)
Employees (consolidated)
Start date
End date
§02

Websites

1 DOMAINS
§03

Business

50
Sterile Clinical Trial ServicesSourcesAdvanced Drug Delivery & Drug-Device Combination ProductsSourcesCommercial Packaging TechnologySourcesClinical Trial ServicesSourcesDevelopment of Sterile FormulationsSourcesLyophilization Cycle DevelopmentSourcesSterile ManufacturingSourcesSterile Fill-Finish & LyophilizationSourcesBulk LyophilizationSourcesPrefilled Syringe ServicesSourcesComplex FormulationsSourcesQuality & Regulatory Services (QRS)SourcesSterile ServicesSourcesNon-Sterile ServicesSourcesDrug-Device Combination ProductsSourcesCold Chain Packaging & LabelingSourcesBiologics PackagingSourcesCompliance & Adherence PackagingSourcesPackaging Design & DevelopmentSourcesStorage, Distribution & ReturnsSourcesclinicalSMART™SourcesClinical Support ServicesSourcesOur Client Platform - pci | bridge™SourcesAdvanced Drug Delivery SystemsSourcesStandard & Specialty Dosage FormsSourcesLaunch & New Product IntroductionSourcesSerialization & Anti-CounterfeitingSourcesPharmaceutical DevelopmentSourcesHigh-Potent Drug DevelopmentSourcesOral Targeted TherapiesSourcesHigh-Potent ManufacturingSourcesHigh-Potent Clinical ManufacturingSourcesHigh-Potent Commercial ManufacturingSourcesActiv-Blister™ SolutionsSourcesTemperature Controlled PackagingSourcespharmaceutical supply chain servicesSourcesClinicalSourcesCommercialSourcesDevelopment and ManufacturingSourcesbiotech capabilitiesSourcesAdvanced Drug Delivery (ADD)Sourcesdrug product capabilities across sterile and non-sterile dosage formsSourcesclinical trial servicesSourcessupply chain managementSourcesclinical packagingSourceslabelingSourcescold chain logisticsSourcesmanufacture-to-market solutionSourcesdevelopment and manufacturingSourcescommercial packaging technologySources
§04

Related companies

0 COMPANIES

—

§05

Network

NETWORK
Drag to move · click to open
§07

News

6 ARTICLES

PCI Expands U.S. Sterile ManufacturingSources

PCI Pharma Services announced major U.S. infrastructure investments exceeding $1 billion to expand its sterile fill-finish and drug-device combination capabilities. Plans include high-speed isolator filling lines for prefilled syringes, cartridges and vials, as well as drug-device combination assembly and packaging.

PCI Pharma Services Secures Strategic InvestmentSources

PCI Pharma Services announced a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, with significant reinvestment from Mubadala. The transaction also includes continued investment from Partners Group and is intended to accelerate PCI’s position in the CDMO sector.

Bedford Facility UpdateSources

PCI Pharma Services will introduce its new 50,000-square-foot sterile fill-finish facility at its Bedford, New Hampshire campus during the BIO International Convention, June 16–19, in Boston. Construction and infrastructure installation are complete, and qualification activities are underway as the facility approaches full-scale GMP production this summer.

PCI Completes Ajinomoto Althea AcquisitionSources

PCI Pharma Services announced it has completed its acquisition of Ajinomoto Althea. The acquisition is part of PCI’s $1 billion investment strategy and enhances its U.S. drug product manufacturing for aseptic filling of prefilled syringes and cartridges. It also furthers PCI’s growth in sterile fill-finish, advanced drug delivery systems and biologics.

PCI to Acquire Ajinomoto AltheaSources

PCI Pharma Services announced it is acquiring the entire equity stake in US-based sterile fill-finish CDMO Ajinomoto Althea. The acquisition will create a large-scale manufacturing hub in the San Diego region, adding aseptic facilities for prefilled syringes, cartridges and high-potency formulations such as ADCs.

PCI Pharma & ChiRhoClin Secure Pancreatic DrugSources

PCI Pharma Services has partnered with ChiRhoClin, Inc. to prevent a shortage of the critical orphan diagnostic drug ChiRhoStim® used for pancreatic disease and cancer testing. The collaboration, completed on a tight schedule, ensures a stable supply of the drug across the United States, benefiting patients nationwide.

§09

Sources & updates

SOURCES
↑